This study aims to investigate whether Mean Platelet Volume (MPV) and other blood count parameters measured at admission can predict mortality in cancer patients admitted to the intensive care unit (ICU). Patients with cancer are highly vulnerable to complications and organ failure, making early risk assessment vital for improving treatment strategies. Researchers will retrospectively review the medical charts and electronic health records of adult patients who stayed in the anesthesia ICU for longer than 24 hours between 2020 and 2025. No new laboratory tests, interventions, or patient contact will occur. The collected data will be analyzed to determine the relationship between initial MPV levels and patient survival outcomes.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients aged 18 years and older.
* Patients with a pathologically or clinically confirmed diagnosis of cancer (solid or hematological malignancies).
* Patients who were admitted to the Anesthesia Intensive Care Unit (ICU) between 2020 and 2025.
* Patients with an ICU length of stay longer than 24 hours.
* Patients with complete medical records, including baseline complete blood count (CBC) and Mean Platelet Volume (MPV) measured at the time of ICU admission.
Exclusion Criteria:
* Patients under the age of 18.
* Patients who stayed in the intensive care unit for less than 24 hours.
* Patients with missing or incomplete medical charts, laboratory data, or survival status records.
* Patients who were readmitted to the ICU during the same hospital stay (only the first admission will be evaluated).
* Patients who received massive blood or platelet transfusions immediately prior to the baseline laboratory measurement, which could artificially alter platelet parameters.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Intensive Care Unit (ICU) Mortality
Timeframe: From the date of ICU admission up to ICU discharge, assessed up to 30 days.
Trial details
NCT IDNCT07656311
SponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital